Physicians' Academy for Cardiovascular Education

GLP-1RAs: What are the future directions in development?

5 Things a cardiologist needs to know about GLP-1 RA

Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - London, United Kingdom

5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

Video navigation menu

  • Obesity drives T2DM and CVD 00:35
  • How do GLP-1RAs reduce CV risk? 03:13
  • Strategies to prevent T2DM and CVD 06:21
  • Barriers to use of GLP-1RAs 09:32


Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.


Prof. John Deanfield, Professor of Cardiology, University College London, United Kingdom.


This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Share this page with your colleagues and friends: